Novartis receives CHMP positive opinion for Enerzair® Breezehaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma
Novartis has announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of its Enerzair® Breezehaler® as a maintenance treatment of asthma in adult patients not adequately controlled with currently recommended maintenance...